Different KIT mutation locations have been reported in the CBF-AML and t(8;21) and inv(16) AML subgroups, which was insufficient for the meta-analysis but still systematically reviewed (Table 4). This evidence concerns the gene CEBPZ and acute myeloid leukemia.